Skip to main content

Frontiers announces $1 million in funding for Clinical Research Scholars Programs

Frontiers: University of Kansas Clinical and Translational Science Institute (KU CTSI) recently announced the awarding of approximately $1 million in funding for its latest round of KL2 and TL1 Scholars Program recipients.

Both the KL2, mentored career award, and TL1, clinical and translational research training, programs are designed to play a key role in addressing the critical need for more clinical and translational researchers in the region. Specifically, the KL2 award is designed to foster the development of new faculty researchers and supports four scholars each for two years. The TL1 program supports research training for two pre- and four post-doctoral training positions. The pre-doctoral awards are for one year and the postdoctoral awards are for two years.

Last fall, candidates from Frontiers-affiliated institutions were eligible to submit applications, and the awardees were chosen through a competitive review process by a committee of officials from member institutions. Frontiers received more than 50 applications for the awards.

Based at the University of Kansas Medical Center, Frontiers accelerates research, stimulates new ideas and supports the researchers of today and tomorrow. KU CTSI is one of 57 similar hubs in the United States that are working to accelerate the process of going from scientific discovery to patient care. Frontiers is supported by a five-year, $25 million grant from the National Center for Advancing Translational Sciences of the National Institutes of Health

This year's recipients include:

Mentored Career Development Awardees (KL2)
Ryan Funk, PharmD, Ph.D., Department of Pharmacy Practice, University of Kansas, "Metabolomic markers of methotrexate response in autoimmune arthritis." Primary mentor: Mara Becker, M.D.

Drew Roberts, PharmD, Ph.D., Department of Preventive Medicine and Public Health, University of Kansas Medical Center, "Patterns and predictors of risky opioid use among breast cancer survivors." Primary mentor: Ed Ellerbeck, M.D.

Amanda Szabo-Reed, Ph.D., Cardiovascular Research Institute, University of Kansas Medical Center, "Examining the influence of metabolic syndrome on the executive control network." Primary mentor: Jeff Burns, M.D.

Jonathan Wagner, D.O., Cardiology and Clinical Pharmacology, Children's Mercy Kansas City, "Statin optimization in pediatrics." Primary mentor: Steven Leeder, PharmD, Ph.D.

Postdoctoral Awardees (TL1)
Natasha Aduloju-Ajijola, Ph.D., Biomedical & Health Informatics, University of Missouri-Kansas City, "Religiously tailoring the ARTAS strength-based system." Primary mentor: Jannette Berkley-Patton, Ph.D.

Colin McCoin, Ph.D., Department of Molecular Integrative Physiology, University of Kansas Medical Center, "Dose- and sex- dependence of reduced skeletal muscle mitochondrial function with statin therapy." Primary mentor: John Thyfault, Ph.D.

Randi Ryan, M.D., Department of Surgery, University of Kansas Medical Center, "Use of patient-derived tissue in 3D tissue culture to examine repositioning of Ciclopirox Olamine for the treatment of esophageal cancer." Primary mentor: Shrikant Anant, Ph.D.

Kathryn Unruh, Ph.D., University of Kansas Life Span Institute, "Systems neuroscience approaches to studying sensorimotor behavior in autism spectrum disorder." Primary mentor: Matt Mosconi, Ph.D.

Pre-doctoral Awardees (TL1)
Carlee Oakley, University of Missouri-Kansas City, "The direct effect of trimethylamine-n-oxide (TMAO) on cardiac muscle contractile mechanics." Primary mentor: Michael Wacker, Ph.D.

Natalie Eisenach, University of Kansas Medical Center, "Let's talk about sex: Does language create a barrier to women reporting and receiving treatment for dyspareunia in the Spanish-speaking community." Primary mentor: Michael Wacker, Ph.D.

Last modified: Sep 28, 2018
ID=x30431